(Press-News.org) MIAMI, FLORIDA (MAY 10, 2024) – Standard of care treatment for acute myeloid leukemia (AML) is safe and effective for adults over 80, according to a study published in Blood Neoplasia. For roughly a quarter of patients, this treatment can durably prolong survival.
AML is an aggressive and often deadly form of blood cancer that can be difficult to treat. For older adults with AML, the conventional treatment consists of a medication called venetoclax combined with a hypomethylating agent (HMA), also known as VEN-HMA. AML treatment is often intensive and can significantly suppress the immune system and put one at risk of other health complications. As a result, some adults with AML, especially those of advanced older age, may be considered ineligible to receive treatment at all and be recommended to pursue palliative care.
“Our study reveals that a significant portion of these patients at the extremes of older age still derive benefit from the VEN-HMA regimen – which is the standard of care for older AML patients and those who are ineligible to receive intensive chemotherapy,” said Justin Watts, M.D., chief of the Leukemia Section at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, and the study’s corresponding author. “While acknowledging it certainly isn’t for everyone, we hope our findings encourage health care providers to thoughtfully explore all treatment avenues for elderly patients with AML, rather than prematurely resorting to HMA alone, best supportive care, or hospice care,” Watts added.
Researchers sought to understand overall survival and remission rates among octo- and nonagenarians (those 80-90 and older) who received VEN-HMA treatment to determine its effectiveness. They analyzed electronic medical records from 154 patients with AML treated with VEN-HMA for the first time between March of 2015 and April of 2022 across six medical institutions in the United States and Italy. Participants had a median age of 82 (range 80-92) and 69% were male. Seventy-seven percent of patients included in the study were newly diagnosed, 10% had relapsed or refractory AML, and for 14%, disease status was unknown.
Sixty-seven percent of patients started treatment with the standard dose and treatment schedule of VEN-HMA, and 72% of the cohort had subsequent modifications of their venetoclax dose or schedule after cycle 1 (e.g., reduction in venetoclax duration). Across the cohort, patients were administered a final median venetoclax dose of 400 mg for 21 days, repeated every 35 days. Patients who demonstrated a response to treatment received a final median venetoclax dose of 200mg of Venetoclax for 21 days, in 35-day cycles.
Approximately 20 to 25% of all treated patients experienced prolonged survival, which encompassed roughly 40% of those who responded to treatment. Median overall survival was 8.1 months, and for those who responded to treatment, it was 13.2 months. At just under eight months follow-up, 23% of patients remained in remission, while 20% were still receiving treatment. Death rates within 30 and 60 days of treatment were 8.5% and 17%, respectively, comparable to the VIALE-A trial.
For patients with newly diagnosed AML without a prior myelodysplastic syndrome (MDS), 73% achieved complete remission or complete remission with incomplete count recovery (CRc), a classification given when a patient’s leukemia cell counts are undetectable, but blood cell counts have not fully returned to normal levels. For patients who achieved CRc, those who received a final venetoclax duration of 14 days or less per cycle had a better average survival time (median of 24.0 months).
Patients whose cancer cells had a mutation in TP53 – a protein vital to preventing abnormal cell growth – exhibited poorer overall survival. Patients with a mutation in the NPM1 protein had very favorable survival, and, interestingly, patients with K/NRAS or FLT3-ITD mutations did not have inferior survival compared to those without.
Notably, this treatment regimen can lead to myelosuppression, reducing the bone marrow’s ability to produce healthy blood cells and weakening the immune system. Older patients, especially those over 80, may be more vulnerable to experiencing myelosuppression, and because of this, researchers suggest reducing the dose and duration of treatment for those at increased risk.
“A second major theme here is that treating this patient population requires adjusting the dosage and duration of VEN-HMA," explained Watts. "Unlike typical adult AML cases, these patients exhibit lower tolerance to Venetoclax, suggesting that they may benefit from a reduced dosage.”
This study is limited by its retrospective format. Further, the median follow-up duration was approximately 7.7 months, and researchers acknowledge their data may have been stronger if this was extended.
Researchers said they plan to study the optimal dose and treatment schedule for this population to further enhance health outcomes. They want to explore the relationship between minimal residual disease (MRD) and molecular subtype on venetoclax exposure and ultimately stopping venetoclax in a subset of durably responding patients. Researchers said they are also interested in developing a better understanding of how treatment affects quality of life.
about Sylvester research on the InventUM Blog and follow @SylvesterCancer on X for the latest news on its research and care.
# # #
Blood Neoplasia (www.bloodneoplasia.org) is an online only, open access journal of the American Society of Hematology (ASH), the world’s largest professional society concerned with the causes and treatment of blood disorders.
# # #
Authors: A complete listing of authors is available in the paper.
Article Title: Venetoclax and Hypomethylating Agents in Octo- and Nonagenarians with Acute Myeloid Leukemia
DOI: 10.1016/j.bneo.2024.100016
END
Consumers are drawn to authenticity when it comes to craft-based firms, and a new study published in the Strategic Entrepreneurship Journal explores what factors can help give credence to such a quality.
The study, authored by Stanislav D. Dobrev of the University of Wisconsin-Milwaukee and J. Cameron Verhaal of Tulane University, looked at how managers in identity-driven markets are challenged to maintain their authenticity as their company’s scale of operations expands. In such craft industries, the authors note, ...
New research being presented at the European Congress on Obesity (ECO) in Venice, Italy (12-15 May) suggests that it is possible to predict if someone is going to gain weight based on their size of their fat cells.
Individuals with large fat cells tend to lose weight over time, while those with small fat cells gain weight, the Swedish study found.
The size and number of fat cells are known to determine fat mass – how much body fat someone has. But their impact on long-term changes in body weight are unknown.
To explore this further, Professor Peter ...
New research being presented at the European Congress on Obesity (ECO) in Venice, Italy (12-15 May), and published in the International Journal of Obesity, could help explain why type 2 diabetes is more common in men than in women.
“Previous studies have shown that men develop type 2 diabetes (TD2) at a younger age and at a lower weight than women and, overall, men appear to be at higher risk of the condition,” says lead researcher Dr Daniel P Andersson, at the Department of Endocrinology, Karolinska University Hospital Huddinge, Stockholm, Sweden. “One reason for ...
New research being presented at the European Congress on Obesity (ECO) in Venice, Italy (12-15 May) has found that poor muscle health is associated with a higher risk of an early death in people living with obesity.
Individuals with adverse muscle composition were up to three times more likely to die during the course of the study than those with healthy muscles, a Swedish study of people in the UK concluded.
“We found that just by looking at muscle composition we can predict which individuals with obesity are most likely to die during the next few years,” says lead researcher Dr Jennifer Linge, of AMRA Medical, ...
The May 2024 issue of the American Journal of Health Economics collects articles on the topic of health equity. The edition was inspired in part by the COVID-19 pandemic, writes guest editor Mónica García-Pérez, and the ways in which that “health crisis exposed the sources of disparities among different US populations that affect access to health care, quality of care, and final health outcomes.”
Consisting of five papers, the issue devotes particular attention to the topics of “race/ethnicity, ...
With the emergence of internet services such as AI-generated content and virtual reality, the demand for global capacity has surged, significantly intensifying pressures on fiber-optic communication systems. To address this surge and reduce operational costs, efforts are underway to develop autonomous driving optical networks (ADONs) with highly-efficient network operations. One of the most important tasks for an ADON is to accurately model and control the optical power evolution (OPE) over fiber links, since it ...
“These results argue that combinations based on immunotherapy may also provide an opportunity for targeting urothelial cancers with low TMB, and provide efficacy superior to classic chemotherapy.”
BUFFALO, NY- May 10, 2024 – A new editorial paper was published in Oncoscience (Volume 11) on April 25, 2024, entitled, “Therapeutic opportunities for hypermutated urothelial carcinomas beyond immunotherapy.”
In this new editorial, researcher Ioannis A. Voutsadakis from Sault Area Hospital and Northern Ontario School of Medicine discusses tumor mutation burden (TMB)—a ...
By Rose Miyatsu, UC Santa Cruz Genomics Institute
Although you may not appreciate them, or have even heard of them, throughout your body, countless microscopic machines called spliceosomes are hard at work. As you sit and read, they are faithfully and rapidly putting back together the broken information in your genes by removing sequences called “introns” so that your messenger RNAs can make the correct proteins needed by your cells.
Introns are perhaps one of our genome’s biggest mysteries. They are DNA sequences that interrupt the sensible protein-coding information ...
Professor Manolya Kavakli is an expert in gamification
Her talk will examine the complex relationship between humans, computers and tech
She will examine how digital developments have the potential to improve lives and modernise industry.
The latest inaugural lecture at Aston University will look at the complex relationship between humans, computers and technology.
Professor Manolya Kavakli will discuss progress so far and offer insights into how to ease into digital transformation for the challenges that lie ahead.
The professor is an expert in gamification, the process of using elements of gaming in non-gaming situations such as learning and training.
She ...
There are 62.5 million internally displaced persons worldwide, according to 2022 data by the UNHCR, the United Nations Refugee Agency. These individuals were forced to leave their homes but remain in the same country.
Prior research has shown that internally displaced persons often experience prejudice and discrimination, as residents in their new locale fear that the migrants may be insurgents or criminals, or compete for jobs.
Now, a new Dartmouth study involving Afghanistan indicates that changing such attitudes is an uphill battle. Given the decades of fighting there, Afghanistan has had one of the largest populations ...
